The sunshine state claims Guild Intern of the Year award

APP2023 has begun with a celebration and announcement of the 2022 MIMS/Guild Intern of the Year – Georgina Morris from LiveLife Pharmacy Bowen Healthcare taking out the coveted award.

The Pharmacy Guild of Australia’s National President, Professor Trent Twomey congratulated Georgina on her award and the recognition that comes from this prestigious accolade.

“Well done to Georgina Morris from LiveLife Pharmacy, representing the community of Bowen in North Queensland.

“Not only do you now hold the title of Intern of the Year, but the opportunity to be here at APP2023 will also give you great exposure to the best educational resources, the latest and most innovative products and services in pharmacy, and an opportunity to network with industry leaders and peers.

“No doubt, immersing yourself in all that the conference offers will inspire you to continue your dedication to community pharmacy,” Professor Twomey said.

Award winner Georgina Morris graciously accepted the award during the opening plenary at APP2023:

“Being named the 2022 MIMS/Guild Intern of the Year is a true honour.

“As an Indigenous student, I felt immense responsibility to relocate to a rural area for my internship to influence the health outcomes of fellow Aboriginal and Torres Strait Islanders members of the community.

“I believe I inspire other First Nations students to pursue a pharmacy career for the opportunity to make a societal impact,” Ms Morris said.

Mr Robert Best, CEO and Executive Director of MIMS Australia and New Zealand congratulated Georgina and said MIMS Australia was pleased to continue to sponsor an award that supported the future of pharmacy.

“For close to 60 years, MIMS has been committed to supporting young healthcare professionals like Georgina across Australia from all parts of the healthcare ecosystem,” Mr Best said.

Text: Pharmacy Guild. 

Must Read

New hope to treat women with early breast cancer

0
For the first time in 15-years women with an invasive form of early breast cancer that has a high risk of returning after initial...